Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines

Evan Tobin, Gerald L Denardo, Nan Zhang, Alan L. Epstein, Cathy Liu, Sally DeNardo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Rituximab is effective in about one half of patients with indolent lymphoma. Even these patients relapse and develop rituximab resistance. To increase potency and circumvent resistance, the anti-lymphoma effects of rituximab, an anti-CD20 MAb, combined with chLym-1, an anti-HLA-DR MAb, were assessed in human lymphoma cell lines by examining growth inhibition and cell death, apoptosis induction, ADCC and CDC. There were additive effects in all assays and synergism in cell lines, such as B35M, which displayed resistance to either MAb alone. In B35M cells, combined rituximab and chLym-1 induced a 27-fold direct reduction in viable cells, whereas equivalent concentrations of rituximab or chLym-1 alone induced only a 1-fold and 10-fold reduction in viable cells, respectively. Because these results occurred at MAb concentrations readily achievable in patients, they suggest that this combination immunotherapy regimen may increase the potency and range of effectiveness of these MAbs in lymphoma patients.

Original languageEnglish (US)
Pages (from-to)944-956
Number of pages13
JournalLeukemia and Lymphoma
Volume48
Issue number5
DOIs
StatePublished - May 2007

Fingerprint

HLA-DR Antigens
Immunotherapy
Lymphoma
Monoclonal Antibodies
Cell Line
Antibody-Dependent Cell Cytotoxicity
Centers for Disease Control and Prevention (U.S.)
Cell Death
Rituximab
Apoptosis
Recurrence
Growth

Keywords

  • CD20
  • HLA-DR
  • Immunotherapy
  • Lym-1
  • Lymphoma
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. / Tobin, Evan; Denardo, Gerald L; Zhang, Nan; Epstein, Alan L.; Liu, Cathy; DeNardo, Sally.

In: Leukemia and Lymphoma, Vol. 48, No. 5, 05.2007, p. 944-956.

Research output: Contribution to journalArticle

@article{986c5a913d8548b79c9f282acfb4f039,
title = "Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines",
abstract = "Rituximab is effective in about one half of patients with indolent lymphoma. Even these patients relapse and develop rituximab resistance. To increase potency and circumvent resistance, the anti-lymphoma effects of rituximab, an anti-CD20 MAb, combined with chLym-1, an anti-HLA-DR MAb, were assessed in human lymphoma cell lines by examining growth inhibition and cell death, apoptosis induction, ADCC and CDC. There were additive effects in all assays and synergism in cell lines, such as B35M, which displayed resistance to either MAb alone. In B35M cells, combined rituximab and chLym-1 induced a 27-fold direct reduction in viable cells, whereas equivalent concentrations of rituximab or chLym-1 alone induced only a 1-fold and 10-fold reduction in viable cells, respectively. Because these results occurred at MAb concentrations readily achievable in patients, they suggest that this combination immunotherapy regimen may increase the potency and range of effectiveness of these MAbs in lymphoma patients.",
keywords = "CD20, HLA-DR, Immunotherapy, Lym-1, Lymphoma, Rituximab",
author = "Evan Tobin and Denardo, {Gerald L} and Nan Zhang and Epstein, {Alan L.} and Cathy Liu and Sally DeNardo",
year = "2007",
month = "5",
doi = "10.1080/10428190701272272",
language = "English (US)",
volume = "48",
pages = "944--956",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines

AU - Tobin, Evan

AU - Denardo, Gerald L

AU - Zhang, Nan

AU - Epstein, Alan L.

AU - Liu, Cathy

AU - DeNardo, Sally

PY - 2007/5

Y1 - 2007/5

N2 - Rituximab is effective in about one half of patients with indolent lymphoma. Even these patients relapse and develop rituximab resistance. To increase potency and circumvent resistance, the anti-lymphoma effects of rituximab, an anti-CD20 MAb, combined with chLym-1, an anti-HLA-DR MAb, were assessed in human lymphoma cell lines by examining growth inhibition and cell death, apoptosis induction, ADCC and CDC. There were additive effects in all assays and synergism in cell lines, such as B35M, which displayed resistance to either MAb alone. In B35M cells, combined rituximab and chLym-1 induced a 27-fold direct reduction in viable cells, whereas equivalent concentrations of rituximab or chLym-1 alone induced only a 1-fold and 10-fold reduction in viable cells, respectively. Because these results occurred at MAb concentrations readily achievable in patients, they suggest that this combination immunotherapy regimen may increase the potency and range of effectiveness of these MAbs in lymphoma patients.

AB - Rituximab is effective in about one half of patients with indolent lymphoma. Even these patients relapse and develop rituximab resistance. To increase potency and circumvent resistance, the anti-lymphoma effects of rituximab, an anti-CD20 MAb, combined with chLym-1, an anti-HLA-DR MAb, were assessed in human lymphoma cell lines by examining growth inhibition and cell death, apoptosis induction, ADCC and CDC. There were additive effects in all assays and synergism in cell lines, such as B35M, which displayed resistance to either MAb alone. In B35M cells, combined rituximab and chLym-1 induced a 27-fold direct reduction in viable cells, whereas equivalent concentrations of rituximab or chLym-1 alone induced only a 1-fold and 10-fold reduction in viable cells, respectively. Because these results occurred at MAb concentrations readily achievable in patients, they suggest that this combination immunotherapy regimen may increase the potency and range of effectiveness of these MAbs in lymphoma patients.

KW - CD20

KW - HLA-DR

KW - Immunotherapy

KW - Lym-1

KW - Lymphoma

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=34547437582&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547437582&partnerID=8YFLogxK

U2 - 10.1080/10428190701272272

DO - 10.1080/10428190701272272

M3 - Article

C2 - 17487739

AN - SCOPUS:34547437582

VL - 48

SP - 944

EP - 956

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 5

ER -